More than 5,600 miles from the company’s home-base in Namur, Belgium, VolitionRx CEO Cameron Reynolds recently interviewed with SNN Live host and CEO Shelly Kraft at the Sixth Annual LD Micro Conference in Bel Air, Calif.
VolitionRx is a life sciences company developing inexpensive, accurate, and scalable cancer detection blood tests. In the live video interview, Reynolds discusses the ongoing clinical trial for the company’s front-line colorectal cancer diagnostic test.
To view the interview visit: https://www.youtube.com/watch?v=mh08N2_LPLg
Reynolds notes that while colonoscopies are the standard procedure for colorectal cancer diagnosis, 50 percent of individuals do not undergo the procedure. Though highly accurate, the testing is highly invasive and costs roughly $2,000.
VolitionRx’s blood diagnostic test, however, is cheaper, quicker and in pre-clinical trials demonstrated significant accuracy. The company hopes that the blood-based tests will encourage more people to get routine testing.
“Blood tests, we think, are very superior for ease and for price,” says Reynolds. “ … Accuracy is very important to us, and that’s why we’ve developed a test that appears to be very accurate in our early stage trials …. The accuracy of our tests …are about 85 percent for both false-negatives and false-positives. For blood tests [this result] is excellent. It’s something we’re very hopeful for, to continue on those sort of numbers in the larger trials we’re doing now.”
The company’s test isn’t designed to replace colonoscopy, which can identify the location of cancerous regions in the bowel, but rather to replace the colonoscopy as an accurate, low-cost and minimally invasive front-line screening test.
Reynolds concludes his interview with SNN Live by briefly discussing his own background, as well as that of the company’s scientific team.
For more information on VolitionRx, visit www.volitionrx.com
Let us hear your thoughts below: